PRLog - March 26, 2014 - SAN JOSE, Calif. -- There’s a lot to know about small cap biotech ETFs. For instance, in order to make the index, companies must have a minimum of $400 million in market capitalization and an adequate amount of liquidity to go with it. Knowing the information behind small cap biotech ETFs helps investors decide if buying the ETF is right for them.
An article from Remonsy ETF Network goes through all the requirements companies need to meet in order to be qualified for the index. After that introduction, the article goes into the cost and associated taxes for investing in small cap biotech ETFs. The article lays out the pros and cons, and ends with the recommendation of the best small cap biotech ETF to buy.
“Small Cap Biotech ETF: SPDR S&P Biotech ETF Analysis” (http://remonsy.com/
To discover a comprehensive look at small cap biotech ETFs, and a suggested ETF to buy, take a look at this article from Remonsy ETF Network: http://remonsy.com/
Remonsy ETF Network publishes free daily tips, a daily newsletter and premium monthly reports based on Remonsy 5 Factor Investing: 1) Scientific Asset Allocation Models 2) Low cost ETF funds, 3) Tax-efficient investing, 4) opportunistic portfolio rebalancing and 5) Market timing doesn’t work. The company does not hold or manage funds, take commissions or receive any fees from investment companies.
About Remonsy and Tom Vaughan:
Tom Vaughan began his financial advisory career in 1987 at a Wall Street-based firm. In 1986, at the age of 23, he founded money management firm Retirement Capital Strategies. He is now taking his investment expertise from more than 26 years as an investment advisor with more than $300 million under management and over 6,000 financial plans created to launch Remonsy ETF Network. Remonsy investment advice focused around ETF funds will be delivered to the growing number of do-it-yourself investors thru daily tips, free newsletters and premium products.